Inbrain Neuroelectronics, a spin-off of the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA, has raised €14.3 million in a Series A funding round led by Asabys Partners and Alta Life Sciences and joined by the Centre for Development of Industrial Technology (CDTI), Catalan Finance Institute (ICF) and international investors Vsquared Ventures and TruVenturo GmbH.

Inbrain is developing graphene-based neuroelectronic therapies for patients with epilepsy, Parkinson and other brain related disorders. Specifically, the company is developing a less-invasive smart neural system, driven by artificial intelligence and big data, that will be able to read and modulate brain activity, detect therapy-specific biomarkers and trigger adaptive responses to obtain optimal results in personalised neurological therapies.

The investment will allow Inbrain to bring this technology  to humans for the first time.

In Europe, brain disorders cost approximately €800 billion per year and affect more than 35% of the population.

This positive news coincided with the presentation by Biocat and CataloniaBio & HealthTech of the investment data for health startups in Catalonia in 2020, with a record €226 million.

Photo: from left to right, José Garrido, co-founder and CSO of Inbrain; Carolina Aguilar, co-founder and CEO of Inbrain; Montserrat Vendrell, managing partner of Alta LS and CataloniaBio & HealthTech board member, and Josep Lluís Sanfeliu, managing partner of Asabys, in Barcelona.